Results 91 to 100 of about 51,902 (295)
Drug Design, Development and Therapy, 2019 Fumi Varyani,1,* Konstantinos Argyriou,2,* Frank Phillips,1,* Eirini Tsakiridou,3 Gordon William Moran2,4 1Queen’s Medical Center, Nottingham University Hospitals NHS Trust, Nottingham, UK; 2Nottingham Digestive Diseases Centre, School of Medicine,
Varyani F +4 more
doaj
Janus Kinase inhibitors in dermatology: a review
Revista da Sociedade Portuguesa de Dermatologia e Venereologia, 2023 Janus Kinases (JAKs) are a subset of cytoplasmic protein tyrosine kinases (TYK), crucial for the initiation of signaling pathways activated by cytokines through phosphorylation and activation of the signal transducer and activator of transcription (STAT)
Bárbara Vieira-Granja, Sofia Magina
doaj
Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis
, 2013 This is the protocol for a review and there is no abstract. The objectives are as follows: To determine the clinical efficacy and safety of JAK1 and JAK2 inhibitors for treating MF generated by hematologic or non-hematologic conditions. © 2013 The Cochrane Collaboration.
Martí-Carvajal A.J. +3 more
openaire +2 more sources
T cells, the next big target in axSpA?
Arthritis &Rheumatology, Accepted Article.Axial spondyloarthritis (axSpA) is a chronic inflammatory disease characterized by complex immune dysregulation, with T cells playing a central role in its pathogenesis. In this review we synthesize current knowledge on diverse T cell subsets in axSpA, their pathogenic mechanisms, and emerging therapeutic strategies targeting these cells.
Mansi K. Aparnathi, Nigil Haroon
wiley +1 more source
CAQ Corner: Basic concepts of transplant immunology
, 2022 Liver Transplantation, EarlyView.
Amanda Cheung, Josh Levitsky
wiley +1 more source
Alterations of T cell activation signalling and cytokine production by postmenopausal estrogen levels [PDF]
, 2009 Background Immunosenescence is an age-associated disorder occurring primarily in T cell compartments, including altered subset composition, functions, and activation.
Lowell T Ku +3 more
core +1 more source
Efficacy, safety and cost‐effectiveness of CAR‐T therapy
British Journal of Clinical Pharmacology, EarlyView.CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher +7 more
wiley +1 more source
TYK2 promotes malignant peripheral nerve sheath tumor progression through inhibition of cell death [PDF]
, 2019 BACKGROUND: Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive sarcomas that arise most commonly in the setting of the Neurofibromatosis Type 1 (NF1) cancer predisposition syndrome.
Bu, Xianzhang +7 more
core +2 more sources
Ruxolitinib: An Oral Janus Kinase 1 and Janus Kinase 2 Inhibitor in the Management of Myelofibrosis [PDF]
Postgraduate Medicine, 2013 Myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) are referred to as the classic Philadelphia chromosome (BCR-ABL1)-negative myeloproliferative neoplasms. Although each has distinct pathologic features, all 3 display alterations in Janus kinase (JAK) signal transduction activator of transcription signaling. Myelofibrosis is
openaire +2 more sources
Clinical Pharmacology &Therapeutics, EarlyView.We evaluated whether concomitant 5‐aminosalicylic acid (5‐ASA) influences clinical remission in patients with ulcerative colitis (UC) receiving Janus kinase inhibitors (JAKi). In this retrospective, multicenter cohort study, UC patients receiving tofacitinib (n = 181), upadacitinib (n = 313), or filgotinib (n = 139) were included.
Antonio Tursi +100 more
wiley +1 more source